X4 Pharmaceuticals, Inc. Forecast, price target & analysts
X4 Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
X4 Pharmaceuticals, Inc. Classifications & Recommendation
X4 Pharmaceuticals, Inc. Price Target
| Target Price | $12.24 |
| Price | $3.01 |
| Potential |
306.65%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target X4 Pharmaceuticals, Inc. 2027 .
The average X4 Pharmaceuticals, Inc. target price is $12.24.
This is
306.65%
register free of charge
$13.65
353.49%
register free of charge
$10.10
235.55%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend X4 Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the X4 Pharmaceuticals, Inc. stock has an average upside potential 2027 of
306.65%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 35.11 | 16.30 |
| 1,271.48% | 53.57% | |
| Net Margin | -225.58% | -401.75% |
| 84.58% | 78.10% |
7 Analysts have issued a sales forecast X4 Pharmaceuticals, Inc. 2026 . The average X4 Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
7 X4 Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average X4 Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.87 | -0.68 |
| 66.55% | 63.64% | |
| P/E | negative | |
| EV/Sales | 10.71 |
7 Analysts have issued a X4 Pharmaceuticals, Inc. forecast for earnings per share. The average X4 Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
X4 Pharmaceuticals, Inc....
Current X4 Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jul 10 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jun 02 2026 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Mar 09 2026 |
| Stifel |
Locked
➜
Locked
|
Locked | Dec 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 10 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 29 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jul 10 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jun 02 2026 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 09 2026 |
|
Locked
Stifel:
Locked
➜
Locked
|
Dec 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 10 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 29 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
